Coloplast A/S (COLOB) Earnings Call Transcripts
Coloplast A/S's Latest Earnings Call - May 12, 2026
Coloplast A/S reported strong Q2 FY2025/26 results, with notable performance in Ostomy Care and Continence Care, driving organic growth. Revenue for the first six months increased by DKK 171 million, or 1%, with organic growth contributing DKK 789 million. However, the Wound & Tissue repair segment underperformed, leading to a revised full-year guidance. The company now expects full-year organic revenue growth of 5% to 6%, with EBIT growth in constant currencies at around 5%. The introduction of new CEO Gavin Wood signals a potential strategic shift, although specific changes remain undefined.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | DKK 9.5 billion (inline) |
| Gross Margin | 67% (miss) |
| Operating Profit | DKK 3.7 billion (miss) |
| EBIT Margin | 26% (miss) |
| Free Cash Flow | DKK 2.7 billion (beat) |
Guidance from management
Coloplast revised its full-year guidance to 5%-6% organic revenue growth and around 5% EBIT growth in constant currencies, citing challenges in the Wound & Tissue repair segment.
What management said
Our Q2 '25/'26 Conference Call. I am Anders Lonning-Skovgaard, CFO of Coloplast, and I'm very happy to introduce our new President and CEO, Gavin Wood who joined the company on May 1. Please turn to Slide #3.
So for me, if I give something more concrete, it would be focusing on value creation. And if there's one area that I typically look at from a strong commercial background, it's commercial execution.
What analysts pressed on
Analysts expressed concerns about the Wound & Tissue repair segment's performance and the sustainability of growth in Interventional Urology. Questions were raised about potential strategic changes under the new CEO, given past underperformance in share price.
Main topics on the call
- Ostomy Care Growth — Ostomy Care achieved 7% organic growth in Q2, driven by the SenSura Mio and Brava products, with strong performance in the U.S. and Europe. Management expects continued momentum and market share gains.
- Continence Care Performance — Continence Care saw 8% organic growth in Q2, led by the Luja catheter portfolio. Management highlighted Luja as a decade-defining innovation.
- Wound & Tissue Repair Challenges — The segment saw a 2% decline in Q2, with management citing external headwinds and a challenging outpatient business. Organic growth guidance was revised due to these issues.
- New CEO Introduction — Gavin Wood, with extensive MedTech experience, emphasized a focus on leadership, talent development, and commercial execution. He is on a 'listening tour' to assess strategic priorities.
Read the full Coloplast A/S transcript (May 12, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Coloplast A/S
Coloplast A/S (COLOB) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on CPSE and is based in DK. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 40 calls on record spanning February 6, 2020 to May 12, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 40 Coloplast A/S earnings call transcripts on record, spanning February 6, 2020 to May 12, 2026. Based on this history, Coloplast A/S reports quarterly. The most recent call on file is dated May 12, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- COLOB
- Exchange
- CPSE
- Country
- DK
- Sector
- Health Care
- Calls on record
- 40
- First call
- February 6, 2020
- Most recent
- May 12, 2026
- Reporting cadence
- quarterly